NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

NASDAQ:NMRA • US6409791000

3.2 USD
-0.05 (-1.54%)
At close: Feb 13, 2026
3.23 USD
+0.03 (+0.94%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NMRA. NMRA was compared to 191 industry peers in the Pharmaceuticals industry. While NMRA seems to be doing ok healthwise, there are quite some concerns on its profitability. NMRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NMRA had negative earnings in the past year.
  • NMRA had a negative operating cash flow in the past year.
  • NMRA had negative earnings in each of the past 5 years.
  • NMRA had a negative operating cash flow in each of the past 5 years.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of NMRA (-132.88%) is worse than 84.29% of its industry peers.
  • Looking at the Return On Equity, with a value of -178.79%, NMRA is doing worse than 73.30% of the companies in the same industry.
Industry RankSector Rank
ROA -132.88%
ROE -178.79%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The number of shares outstanding for NMRA has been increased compared to 1 year ago.
  • NMRA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for NMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -5.37, we must say that NMRA is in the distress zone and has some risk of bankruptcy.
  • NMRA has a worse Altman-Z score (-5.37) than 64.40% of its industry peers.
  • A Debt/Equity ratio of 0.15 indicates that NMRA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.15, NMRA is in line with its industry, outperforming 47.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -5.37
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 6.85 indicates that NMRA has no problem at all paying its short term obligations.
  • NMRA has a better Current ratio (6.85) than 70.68% of its industry peers.
  • NMRA has a Quick Ratio of 6.85. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NMRA (6.85) is better than 71.20% of its industry peers.
Industry RankSector Rank
Current Ratio 6.85
Quick Ratio 6.85
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • NMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.99%, which is quite impressive.
EPS 1Y (TTM)22.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.60% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.05%
EPS Next 2Y15.18%
EPS Next 3Y10%
EPS Next 5Y11.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NMRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.18%
EPS Next 3Y10%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (2/13/2026, 8:00:01 PM)

After market: 3.23 +0.03 (+0.94%)

3.2

-0.05 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners52%
Inst Owner Change3.81%
Ins Owners5.33%
Ins Owner Change0%
Market Cap527.33M
Revenue(TTM)N/A
Net Income(TTM)-236.30M
Analysts78.67
Price Target9.33 (191.56%)
Short Float %4.96%
Short Ratio3.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.08%
Min EPS beat(2)6%
Max EPS beat(2)12.16%
EPS beat(4)3
Avg EPS beat(4)6.72%
Min EPS beat(4)-10.01%
Max EPS beat(4)18.71%
EPS beat(8)5
Avg EPS beat(8)-0.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.26%
PT rev (3m)30.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.37%
EPS NY rev (1m)0.4%
EPS NY rev (3m)-1.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.99
P/tB 3.99
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.88%
ROE -178.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.85
Quick Ratio 6.85
Altman-Z -5.37
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
EPS Next Y5.05%
EPS Next 2Y15.18%
EPS Next 3Y10%
EPS Next 5Y11.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y14.41%
EBIT Next 5Y3.09%
FCF growth 1Y-9.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.04%
OCF growth 3YN/A
OCF growth 5YN/A

NEUMORA THERAPEUTICS INC / NMRA FAQ

What is the fundamental rating for NMRA stock?

ChartMill assigns a fundamental rating of 1 / 10 to NMRA.


Can you provide the valuation status for NEUMORA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to NEUMORA THERAPEUTICS INC (NMRA). This can be considered as Overvalued.


Can you provide the profitability details for NEUMORA THERAPEUTICS INC?

NEUMORA THERAPEUTICS INC (NMRA) has a profitability rating of 0 / 10.


What is the expected EPS growth for NEUMORA THERAPEUTICS INC (NMRA) stock?

The Earnings per Share (EPS) of NEUMORA THERAPEUTICS INC (NMRA) is expected to grow by 5.05% in the next year.